Recida Therapeutics
Menlo Park, US · Founded 2016 · Delaware corporation · 1 known investors
Founders & leadership
YG
Yigong GeNamed on SEC filing
MS
Michael SavinoNamed on SEC filing
DS
David SocksNamed on SEC filing
Board
PH
Investors · 1
Reported raises · per SEC filings
Form D private placements$5.7M disclosed across 1 round · 2018
▶$5.7MraisedJul 2018 · 1 investors · BiotechnologyRule 506(b)
▶$5.7MraisedJul 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick HeronDirector
- Yigong GeExecutive Officer, Director
- Michael SavinoExecutive Officer
- David SocksDirector
- Offering amount
- $10.7M
- Amount sold
- $5.7M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Recida Therapeutics's investors?
- Recida Therapeutics's investors include Frazier Life Sciences.
- How much funding has Recida Therapeutics raised?
- Recida Therapeutics has disclosed $5.7M raised across 1 round.
- Where is Recida Therapeutics headquartered?
- Recida Therapeutics is headquartered in Menlo Park, US.